Who this is for
This page is for people with hormone receptor–positive, HER2-negative early breast cancer who have been told their cancer has not spread to the lymph nodes, and who are deciding whether chemotherapy is necessary.
Being advised that chemotherapy may not be needed can feel both relieving and confusing. Many patients wonder: “Are we doing enough?” The TAILORx trial helped answer that question with high-quality evidence, showing that many women can safely avoid chemotherapy without compromising long-term outcomes.
Why this question mattered
For years, patients with hormone receptor–positive, HER2-negative early breast cancer often received chemotherapy based on tumour size and grade alone.
However, many of these cancers behave in a more indolent, hormone-driven way.
The key question was:
Can genomic testing identify patients who do not benefit from chemotherapy?
TAILORx was designed to answer that.
What TAILORx studied
TAILORx was a large, prospective, international phase III clinical trial involving over 10,000 women with:
• Hormone receptor–positive
• HER2-negative
• Node-negative early breast cancer
All participants underwent genomic testing using the Oncotype DX recurrence score. This test is done on initial tumour tissue biopsy/surgical specimen with no additional blood or tissue requirements.
Patients with intermediate scores (11–25) were randomly assigned to:
• Endocrine therapy alone
• Chemotherapy plus endocrine therapy
This was the group where uncertainty existed.
Key statistical results
• In women over age 50 with recurrence score 11–25, invasive disease-free survival showed no meaningful benefit from chemotherapy.
• 9-year invasive disease-free survival in this group was approximately 83–84% with endocrine therapy alone.
• Hazard ratio for chemotherapy benefit in the overall intermediate group was approximately 1.08 (no significant advantage).
What this means
A hazard ratio close to 1.0 indicates no significant reduction in recurrence risk from adding chemotherapy in most postmenopausal women within the intermediate genomic risk range.
In other words, for many women over 50 with node-negative disease and recurrence score 11–25, chemotherapy did not improve outcomes.
There was nuance:
• Women aged 50 or younger with recurrence scores 16–25 showed some chemotherapy benefit.
• Very low recurrence scores (0–10) had excellent outcomes with endocrine therapy alone.
TAILORx did not eliminate chemotherapy.
It refined its use.
Why this matters in Melbourne and Australia
In Australia, genomic assays such as Oncotype DX are used selectively in appropriate node-negative, hormone receptor–positive breast cancers to help guide chemotherapy decisions.
In Melbourne clinical practice, decisions often consider:
• Tumour size and grade
• Patient age
• Recurrence score
• Overall health and preferences
TAILORx shifted the standard from “chemotherapy by default” to “chemotherapy when benefit is proven.”
That distinction is important.
Why this matters emotionally
Many patients fear that declining chemotherapy may reduce their chance of cure.
TAILORx reassured a large group of women that endocrine therapy alone was sufficient — and that avoiding chemotherapy did not compromise survival.
That is not undertreatment.
It is precision treatment.
International patients, including Sri Lanka
Patients from Sri Lanka and other countries sometimes seek clarification regarding genomic testing and whether chemotherapy is necessary.
Access to genomic assays may vary by healthcare system. However, the biological principle established by TAILORx is global: not all early breast cancers require chemotherapy, even if they are invasive.
A structured review of pathology and genomic risk can clarify the safest course.
Why TAILORx remains important
TAILORx is one of the most practice-changing early breast cancer trials of the past decade.
It demonstrated that:
• Genomic risk can guide chemotherapy decisions
• Many women can safely avoid chemotherapy
• Treatment intensity should match biological risk
This reflects the broader evolution of oncology: less treatment where it adds no benefit, more precision where it does.
Key Takeaway
• TAILORx showed that many women with node-negative, hormone receptor–positive breast cancer do not benefit from chemotherapy.
• A recurrence score of 11–25 in women over 50 did not show improved outcomes with chemotherapy (hazard ratio ~1.08).
• Genomic testing helps personalise treatment intensity rather than relying on tumour size alone.